Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies.
The development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs.
Capietto
Aude-Hélène
AH
INSERM U563, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France.
Keirallah
Samarh
S
Gross
Emilie
E
Dauguet
Nicolas
N
Laprévotte
Emilie
E
Jean
Christine
C
Gertner-Dardenne
Julie
J
Bezombes
Christine
C
Quillet-Mary
Anne
A
Poupot
Mary
M
Ysebaert
Loic
L
Laurent
Guy
G
Fournié
Jean-Jacques
JJ
D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology; D016503:Drug Delivery Systems / Q000379:methods*; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D008954:Models, Biological; D008958:Models, Molecular; D011993:Recombinant Fusion Proteins
D000911:Antibodies, Monoclonal; D011993:Recombinant Fusion Proteins